CD40LG and COVID-19: Since anti-ACE2 IgM autoantibodies have features of T cell–independent responses, this may provide an important opportunity to use short-term immune-focused therapies in incipient severe COVID-19 (consistent with the dexamethasone results; ref. 12) rather than the deeper immunosuppression needed for T cell–driven processes.